A Combination Study of Durvalumab plus Olaparib in an Unselected Population with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Descriptors:

NOTICE: The appearance of hyperlinks does not constitute endorsement by the DTIC of non-U.S. Government sites or the information, products, or services contained therein. Although the DTIC may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website. The DTIC bears no responsibility for the accuracy, legality or content of the external website or for that of subsequent links. Contact the external website for answers to questions regarding its content. Please let us know about existing external links which you believe are inappropriate.

View The Document

Accession Number:

AD1190938

Title: